Literature DB >> 2327269

Nicotine counteracts midbrain dopamine cell dysfunction induced by prefrontal cortex inactivation.

C S Tung1, J Grenhoff, T H Svensson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2327269     DOI： 10.1111/j.1748-1716.1990.tb08868.x

Source DB:  PubMed          Journal:  Acta Physiol Scand        ISSN： 0001-6772


× No keyword cloud information.
  6 in total

Review 1.  Neurotensin agonists: potential in the treatment of schizophrenia.

Authors:  Mona Boules; Amanda Shaw; Paul Fredrickson; Elliott Richelson
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

Review 2.  Nicotinic mechanisms in the treatment of psychotic disorders: a focus on the α7 nicotinic receptor.

Authors:  Ann Olincy; Robert Freedman
Journal:  Handb Exp Pharmacol       Date:  2012

Review 3.  Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.

Authors:  Ann Olincy; Karen E Stevens
Journal:  Biochem Pharmacol       Date:  2007-07-17       Impact factor: 5.858

Review 4.  Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia.

Authors:  Laura F Martin; William R Kem; Robert Freedman
Journal:  Psychopharmacology (Berl)       Date:  2004-02-19       Impact factor: 4.530

5.  Unusual effects of nicotine as a psychostimulant on ambulatory activity in mice.

Authors:  Toyoshi Umezu
Journal:  ISRN Pharmacol       Date:  2012-03-20

Review 6.  Targeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational Biomarker.

Authors:  Kenji Hashimoto
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.